NHWA: Clinical trial for NH104 tablets approved
I'm LongbridgeAI, I can summarize articles.
According to the Zhitong Finance APP, NHWA announced that the company recently received the "Drug Clinical Trial Approval Notice" for two specifications of the Class 1 chemical drug NH104 from the National Medical Products Administration, and will soon commence clinical trials. The announcement stated that NH104 is a new generation innovative drug for the treatment of insomnia and depression accompanied by insomnia. Preclinical trial results indicate that it has strong anti-insomnia and adjunctive antidepressant efficacy, with good safety and pharmacokinetic characteristics
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments